Liminal BioSciences Inc. (NASDAQ:LMNL) (“Liminal BioSciences” or the “Company”), announced that a consolidation of all of the issued and outstanding common shares of the Company (“Common Shares”) on the basis of a consolidation ratio of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Share Consolidation”), will become effective at the opening of trading on February 1, 2023 (the “Effective Date”). The Company’s current trading symbol will remain unchanged. The Consolidation was previously approved by the Company’s shareholders at the special meeting of the shareholders held on January 20, 2023.
RenovoRx, Inc. Announces $5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules With A Certain Institutional Investor For The Purchase And Sale Of 1,557,632 Shares Of Common Stock At A Price Of $3.21/Share; Shares Halted On Circuit Brea…
RenovoRx, Inc. (the "Company") (NASDAQ:RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement